UroGen Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 7th, 2025
UroGen Pharma (NASDAQ: URGN), a biotechnology company focused on urothelial and specialty cancer treatments, will release its Q2 2025 financial results on Thursday, August 7th, 2025, before market open.
The company will host a conference call and live audio webcast at 10:00 AM ET on the same day. Investors can access the webcast through UroGen's Investor Relations website, with a replay available for approximately 30 days after the event.
UroGen Pharma (NASDAQ: URGN), un'azienda biotecnologica specializzata in trattamenti per il cancro uroteliale e oncologie specializzate, pubblicherà i suoi risultati finanziari del secondo trimestre 2025 giovedì 7 agosto 2025, prima dell'apertura dei mercati.
La società terrà una conference call e una trasmissione audio in diretta alle 10:00 AM ET dello stesso giorno. Gli investitori potranno accedere alla trasmissione tramite il sito web delle Relazioni con gli Investitori di UroGen, con una replica disponibile per circa 30 giorni dopo l'evento.
UroGen Pharma (NASDAQ: URGN), una empresa biotecnológica enfocada en tratamientos para el cáncer urotelial y especialidades oncológicas, publicará sus resultados financieros del segundo trimestre de 2025 el jueves 7 de agosto de 2025, antes de la apertura del mercado.
La compañía realizará una llamada conferencia y una transmisión de audio en vivo a las 10:00 AM ET ese mismo día. Los inversores podrán acceder a la transmisión a través del sitio web de Relaciones con Inversores de UroGen, con una repetición disponible aproximadamente por 30 días después del evento.
UroGen Pharma (NASDAQ: URGN)는 요로상피 및 특수 암 치료에 집중하는 생명공학 회사로, 2025년 2분기 재무 실적을 2025년 8월 7일 목요일, 시장 개장 전 발표할 예정입니다.
회사는 같은 날 오전 10:00 AM ET에 컨퍼런스 콜과 라이브 오디오 웹캐스트를 진행합니다. 투자자들은 UroGen의 투자자 관계 웹사이트를 통해 웹캐스트에 접속할 수 있으며, 행사가 끝난 후 약 30일간 다시보기 서비스를 이용할 수 있습니다.
UroGen Pharma (NASDAQ : URGN), une entreprise biotechnologique spécialisée dans les traitements du cancer urothélial et des cancers spécialisés, publiera ses résultats financiers du deuxième trimestre 2025 le jeudi 7 août 2025, avant l'ouverture des marchés.
La société organisera une conférence téléphonique et une retransmission audio en direct à 10h00 ET le même jour. Les investisseurs pourront accéder à la retransmission via le site web des Relations Investisseurs d'UroGen, avec une rediffusion disponible pendant environ 30 jours après l'événement.
UroGen Pharma (NASDAQ: URGN), ein Biotechnologieunternehmen, das sich auf urotheliale und spezialisierte Krebstherapien konzentriert, wird am Donnerstag, den 7. August 2025, vor Markteröffnung seine Finanzergebnisse für das zweite Quartal 2025 veröffentlichen.
Das Unternehmen wird am selben Tag um 10:00 Uhr ET eine Telefonkonferenz und einen Live-Audio-Webcast abhalten. Investoren können über die Investor-Relations-Website von UroGen auf den Webcast zugreifen, eine Wiederholung steht etwa 30 Tage nach der Veranstaltung zur Verfügung.
- None.
- None.
Conference Call and Webcast Scheduled for Thursday, August 7th, 2025, at 10:00 AM ET
PRINCETON, N.J., July 29, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will report second quarter 2025 financial results on Thursday, August 7th, 2025, prior to the open of the stock market. The announcement will be followed by a live audio webcast and conference call at 10:00 AM Eastern Time.
A live public webcast of the earnings conference call can be accessed on UroGen’s Investor Relations website. Following the live webcast, a replay will be available on the site for approximately 30 days.
About UroGen Pharma Ltd.
UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel reverse-thermal hydrogel, a proprietary sustained-release, hydrogel-based platform technology that has the potential to improve the therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. Our first product is approved to treat low-grade upper tract urothelial cancer, and our second product is the first and only FDA-approved treatment for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer. Both medicines are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel. Visit www.UroGen.com to learn more or follow us on X, @UroGenPharma.
INVESTOR CONTACT:
Vincent Perrone
Senior Director, Investor Relations
vincent.perrone@urogen.com
609-460-3588 ext. 1093
MEDIA CONTACT:
Cindy Romano
Director, Corporate Communications
cindy.romano@urogen.com
609-460-3583 ext. 1083
FAQ
When will UroGen Pharma (URGN) report Q2 2025 earnings?
What time is UroGen's Q2 2025 earnings call?
How can investors access UroGen's Q2 2025 earnings call?
What does UroGen Pharma (URGN) specialize in?
